Drugs / HPIV2 Vaccine
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT01139437 | Jun 2010 → Sep 2015 | parainfluenza virus type 2 infectious disease | National Institute of Allergy and Infectious Diseases (NIAID) | Completed | No outcome recorded |
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | HPIV2 Vaccine | ClinicalTrials.gov intervention name — accepted as the source's own label NCT01139437 ↗ |
| Known as | rHPIV2 15C/948L/Δ1724 Lot PIV2#109C | “A Phase I Study of the Safety and Immunogenicity of the Recombinant Live-Attenuated Human Parainfluenza Type 2 Virus Vaccine, rHPIV2 15C/948L/Δ1724 Lot PIV2#109C, Delivered as...” NCT01139437 ↗ |
| Modality | Vaccine | “live attenuated intranasally administered vaccine” NCT01139437 ↗ |
| Route | Intranasal | “The vaccine will be administered as a nose drop” NCT01139437 ↗ |